Advertisement

Drugs

pp 1–9 | Cite as

Adult-Onset Still’s Disease: Molecular Pathophysiology and Therapeutic Advances

  • Paolo Sfriso
  • Sara Bindoli
  • Paola Galozzi
Leading Article
  • 36 Downloads

Abstract

Adult-onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology generally characterized by persistent high spiking fever, evanescent rash, and polyarthritis. The pathogenesis of AOSD is only partially known. The pivotal role of macrophage cell activation, which leads to T-helper 1 (Th1) cell cytokine activation, is now well-established in AOSD. Moreover, pro-inflammatory cytokines such as interleukin (IL)-1, -6, and -18 seem to play a key role in this disorder, giving rise to the development of new targeted therapies. For years, treatment of AOSD has been largely empirical, using nonsteroidal anti-inflammatory drugs, corticosteroids, and disease-modifying antirheumatic drugs. Patients with steroid- and methotrexate-refractory AOSD can now benefit from efficient and well-tolerated biologic agents such as IL-1, IL-6, and tumor necrosis factor-α antagonists.

Notes

Compliance with Ethical Standards

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Conflict of interest

Paolo Sfriso, Sara Bindoli, and Paola Galozzi have no conflicts of interest.

References

  1. 1.
    Kadavath S, Efthimiou P. Adult-onset Still’s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med. 2015;47:6–14.CrossRefPubMedGoogle Scholar
  2. 2.
    Sfriso P, Priori R, Valesini G, Rossi S, Montecucco CM, D’Ascanio A, et al. Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol. 2016;35:1683–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–30.PubMedGoogle Scholar
  4. 4.
    Maria AT, Le Quellec A, Jorgensen C, Touitou I, Rivière S, Guilpain P. Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13:1149–59.CrossRefPubMedGoogle Scholar
  5. 5.
    Pouchot J, Fautrel B. Maladie de Still de l’adulte. In: Piette JC, Meyer O, Sibilia J, editors. Médecine/Sciences F. Maladies et syndromes systémiques, 5ème édition Paris: Médecine Sciences Flammarion; 2008; vol. 1. p. 449–68.Google Scholar
  6. 6.
    Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still’s disease. Assoc Chron Articul Dis Rheumatol (Oxford). 2001;40:1398–404.CrossRefGoogle Scholar
  7. 7.
    Magadur-Joly G, Billaud E, Barrier JH, Pennec YL, Masson C, Renou P, et al. Epidemiology of adult Still’s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis. 1995;54:587–90.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Wakai K, Ohta A, Tamakoshi A, Ohno Y, Kawamura T, Aoki R, et al. Estimated prevalence and incidence of adult Still’s disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol. 1997;7:221–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Evensen KJ, Nossent HC. Epidemiology and outcome of adult-onset Still’s disease in Northern Norway. Scand J Rheumatol. 2006;35:48–51.CrossRefPubMedGoogle Scholar
  10. 10.
    Jamilloux Y, Gerfaud-Valentin M, Martinon F, Belot A, Henry T, Seve P. Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res. 2015;61:53–62.CrossRefPubMedGoogle Scholar
  11. 11.
    Nirmala N, Brachat A, Feist E, Blank N, Specker C, Witt M, et al. Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J. 2015;13:50.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Sampalis JS, Esdaile JM, Medsger TA, Partridge AJ, Yeadon C, Senécal JL, et al. A controlled study of the long-term prognosis of adult Still’s disease. Am J Med. 1995;98:384–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Terkeltaub R, Esdaile J, Décary F, Harth M, Lister J, Lapointe N. HLA-Bw35 and prognosis in adult Still’s disease. Arthritis Rheum. 1981;12:1469–72.CrossRefGoogle Scholar
  14. 14.
    Joung CI, Lee HS, Lee SW, Kim CG, Song YH, Jun JB, et al. Association between HLA-DR B1 and clinical features of adult onset Still’s disease in Korea. Clin Exp Rheumatol. 2003;21:489–92.PubMedGoogle Scholar
  15. 15.
    Sugiura T, Kawaguchi Y, Harigai M, Terajima-Ichida H, Kitamura Y, Furuya T, et al. Association between adult-onset Still’s disease and interleukin-18 gene polymorphisms. Genes Immun. 2002;3:394–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Wang FF, Huang XF, Shen N, Leng L, Bucala R, Chen SL, et al. A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still’s disease. Arthritis Res Ther. 2013;15:R65.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102:1369–76.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:1505–15.Google Scholar
  19. 19.
    Sighart R, Rech J, Hueber A, Blank N, Löhr S, Reis A, et al. Evidence for genetic overlap between adult onset Still’s disease and hereditary periodic fever syndromes. Rheumatol Int. 2018;38:111–20.CrossRefPubMedGoogle Scholar
  20. 20.
    Wouters JM, van der Veen J, van de Putte LB, de Rooij DJ. Adult onset Still’s disease and viral infections. Ann Rheum Dis. 1988;47:764–7.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Balleari E, Cutolo M, Accardo S. Adult-onset Still’s disease associated to toxoplasma gondii infection. Clin Rheumatol. 1991;10:326–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Liozon E, Ly KH, Vidal-Cathala E, Fauchais AL. Adult-onset Still’s disease as a manifestation of malignancy: report of a patient with melanoma and literature review. Rev Med Interne. 2014;35:60–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Chen DY, Lin CC, Chen YM, Lan JL, Hung WT, Chen HH, et al. Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still’s disease. Arthritis Res Ther. 2013;15:R39.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still’s disease. Autoimmun Rev. 2014;13:708–22.CrossRefPubMedGoogle Scholar
  25. 25.
    Komiya A, Matsui T, Nogi S, Iwata K, Futami H, Takaoka H, et al. Neutrophil CD64 is upregulated in patients with active adult-onset Still’s disease. Scand J Rheumatol. 2012;41:156–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, et al. Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol. 2003;30:2422–7.PubMedGoogle Scholar
  27. 27.
    Matsui K, Tsuchida T, Hiroishi K, Tominaga K, Hayashi N, Hada T, et al. High serum level of macrophage-colony stimulating factor (M-CSF) in adult-onset Still’s disease. Rheumatology (Oxford). 1999;38:477–8.CrossRefGoogle Scholar
  28. 28.
    Hoshino T, Ohta A, Yang D, Kawamoto M, Kikuchi M, Inoue Y, et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still’s disease. J Rheumatol. 1998;25:396–8.PubMedGoogle Scholar
  29. 29.
    Zou YQ, Lu LJ, Li SJ, Zeng T, Wang XD, Bao CD, et al. The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still’s disease. Clin Biochem. 2008;41:519–24.CrossRefPubMedGoogle Scholar
  30. 30.
    Chen DY, Lan JL, Lin FJ, Hsieh TY. Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still’s disease. Arthritis Rheum. 2005;53:320–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Lee SJ, Cho YN, Kim TJ, Park SC, Park DJ, Jin HM, et al. Natural killer T cell deficiency in active adult-onset Still’s Disease: correlation of deficiency of natural killer T cells with dysfunction of natural killer cells. Arthritis Rheum. 2012;64:2868–77.CrossRefPubMedGoogle Scholar
  32. 32.
    Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford). 2003;42:375–9.CrossRefGoogle Scholar
  33. 33.
    Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood. 2009;113:2324–35.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hsieh CW, Chen YM, Lin CC, Tang KT, Chen HH, Hung WT, et al. Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset still disease. J Rheumatol. 2017;44:1142–50.CrossRefPubMedGoogle Scholar
  35. 35.
    Chen DY, Chen YM, Chen HH, Hsieh CW, Gung NR, Hung WT, et al. Human parvovirus B19 nonstructural protein NS1 activates NLRP3 inflammasome signaling in adult-onset Still’s disease. Mol Med Rep. 2018;17:3364–71.PubMedGoogle Scholar
  36. 36.
    Antoniou KM, Margaritopoulos GA, Giannarakis I, Choulaki C, Fountoulakis N, Siafakas NM, et al. Adult onset Still’s disease: a case report with a rare clinical manifestation and pathophysiological correlations. Case Rep Med. 2013;2013:981232.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still’s disease. Ann Rheum Dis. 2004;63:1300–6.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. The associations of circulating CD4+CD25 high regulatory T cells and TGF- b with disease activity and clinical course in patients with adult-onset Still’s disease. Connect Tissue Res. 2010;51:370–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol. 2004;31:2189–98.PubMedGoogle Scholar
  40. 40.
    Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell. 2010;140:784–90.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Rooney T, Murphy E, Benito M, Roux-Lombard P, FitzGerald O, Dayer J-M, et al. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis. 2004;63:1393–8.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Priori R, Barone F, Alessandri C, Colafrancesco S, McInnes IB, Pitzalis C, et al. Markedly increased IL-18 liver expression in adult-onset Still’s disease-related hepatitis. Rheumatology (Oxford). 2011;50:776–80.CrossRefGoogle Scholar
  43. 43.
    Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still’s disease. Arthritis Rheum. 2001;44:550–60.CrossRefPubMedGoogle Scholar
  44. 44.
    Maruyama J, Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol. 2010;37:967–73.CrossRefPubMedGoogle Scholar
  45. 45.
    Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis. 2018;77:840–7.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Scheinberg MA, Chapira E, Fernandes ML, Hubscher O. Interleukin 6: a possible marker of disease activity in adult onset Still’s disease. Clin Exp Rheumatol. 1996;14:653–5.PubMedGoogle Scholar
  47. 47.
    Chen DY, Chen YM, Lan JL, Lin CC, Chen HH, Hsieh CW. Potential role of Th17 cells in the pathogenesis of adult-onset Still’s disease. Rheumatology (Oxford). 2010;49:2305–12.CrossRefGoogle Scholar
  48. 48.
    Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood. 2005;105:1648–51.CrossRefPubMedGoogle Scholar
  49. 49.
    Canna SW. Interferon-γ: friend or foe in systemic juvenile idiopathic arthritis and adult Still’s Disease. Arthritis Rheumatol. 2014;66:1072–6.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Avau A, Mitera T, Put S, Put K, Brisse E, Filtjens J, et al. Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund’s complete adjuvant: regulation by interferon-γ. Arthritis Rheumatol. 2014;66:1340–51.CrossRefPubMedGoogle Scholar
  51. 51.
    Kasama T, Furuya H, Yanai R, Ohtsuka K, Takahashi R, Yajima N, et al. Correlation of serum CX3CL1 level with disease activity in adult-onset Still’s disease and significant involvement in hemophagocytic syndrome. Clin Rheumatol. 2012;31:853–60.CrossRefPubMedGoogle Scholar
  52. 52.
    Govoni M, Bortoluzzi A, Rossi D, Modena V. How I treat patients with adult onset Still’s disease in clinical practice. Autoimmun Rev. 2017;16:1016–23.CrossRefPubMedGoogle Scholar
  53. 53.
    Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum. 2010;62:2530–5.CrossRefPubMedGoogle Scholar
  54. 54.
    Wouters JM, van de Putte LB. Adult-onset Still’s disease; clinical and laboratory features, treatment and progress of 45 cases. QJM. 1986;61:1055–65.PubMedGoogle Scholar
  55. 55.
    Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset Still disease: manifestations, treatments, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91–9.CrossRefGoogle Scholar
  56. 56.
    Kim YJ, Koo BS, Kim YG, Lee CK, Yoo B. Clinical features and prognosis in 82 patients with adult-onset Still’s disease. Clin Exp Rheumatol. 2014;32:28–33.PubMedGoogle Scholar
  57. 57.
    Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70:118–36.CrossRefGoogle Scholar
  58. 58.
    Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E, et al. Response to interleukin-1 inhibitors in 140 italian patients with adult-onset still’s disease: a multicentre retrospective observational study. Front Pharmacol. 2017;8:369.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Al-Homood IA. Biologic treatments for adult-onset Still’s disease. Rheumatology (Oxford). 2014;53:32–8.CrossRefGoogle Scholar
  60. 60.
    Cavagna L, Caporali R, Epis O, Bobbio-Pallavicini F, Montecucco C. Infliximab in the treatment of adult Still’s disease refractory to conventional therapy. Clin Exp Rheumatol. 2001;19:329–32.PubMedGoogle Scholar
  61. 61.
    Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, et al. Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum. 2002;46:1171–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Fautrel B, Sibilia J, Mariette X, Combe B. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262–6.CrossRefPubMedGoogle Scholar
  63. 63.
    Benucci M, Li GF, Del Rosso A, Manfredi M. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still’s disease: the first case report. Clin Exp Rheumatol. 2005;23:733.PubMedGoogle Scholar
  64. 64.
    Rech J, Ronneberger M, Englbrecht M, Finzel S, Katzenbeisser J, Manger K, et al. Successful treatment of adult-onset Still’s disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade. Ann Rheum Dis. 2011;70:390–2.CrossRefPubMedGoogle Scholar
  65. 65.
    Aikawa NE, Ribeiro AC, Saad CG, Pereira RM, Levy M, Silva CA, et al. Is anti-TNF switching in refractory Still’s disease safe and effective? Clin Rheumatol. 2011;30:1129–34.CrossRefPubMedGoogle Scholar
  66. 66.
    Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720–32.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Ortiz-Sanjan F, Blanco R, Riancho-Zarrabeitia L, Castañeda S, Olivé A, Riveros A, et al. Efficacy of anakinra in refractory adult-onset Still’s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore). 2015;94:e1554.CrossRefGoogle Scholar
  68. 68.
    Kone-Paut I, Piram M. Targeting interleukin-1 b in CAPS (cryopyrin-associated periodic) syndromes: what did we learn? Autoimmun Rev 2012;12:77e80.Google Scholar
  69. 69.
    Giampietro C, Fautrel B. Anti-interleukin-1 agents in adult onset still’s disease. Int J Inflam. 2012;2012:317820.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302–8.CrossRefPubMedGoogle Scholar
  71. 71.
    Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545–55.CrossRefPubMedGoogle Scholar
  72. 72.
    Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study. Arthritis Res Ther. 2011;13:R91.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN. Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis. 2007;66:842–3.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Guignard S, Dien G, Dougados M. Severe systemic inflammatory response syndrome in a patient with adult onset Still’s disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol. 2007;25:758–9.PubMedGoogle Scholar
  75. 75.
    Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557–67.CrossRefPubMedGoogle Scholar
  76. 76.
    Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL-1 b long-acting inhibitor, in refractory adult-onset Still’s disease. Semin Arthritis Rheum. 2012;42:201–5.CrossRefPubMedGoogle Scholar
  77. 77.
    Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, et al. Efficacy and safety of canakinumab in patients with Still’s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol. 2018. (Epub ahead of print).Google Scholar
  78. 78.
    Petryna O, Cush JJ, Efthimiou P. IL-1 trap rilonacept in refractory adult onset Still’s disease. Ann Rheum Dis. 2012;71:2056–7.CrossRefPubMedGoogle Scholar
  79. 79.
    Henderson C, Wilson M, Pham TH, Dolan G, Gobbo A, Snyder C, et al. Safety and efficacy of IL-1 trap in resistant adult onset Still’s disease: 24 month follow-up of open label treatment and biomarkers of response. Arthritis Rheum. 2010;62:1831.Google Scholar
  80. 80.
    Ortiz-Sanjuan F, Blanco R, Calvo-Rio V, Narvaez J, Rubio Romero E, Olive A, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 2014;66(6):1659–65.CrossRefPubMedGoogle Scholar
  81. 81.
    Cipriani P, Ruscitti P, Carubbi F, Pantano I, Liakouli V, Berardicurti O, et al. Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series. Clin Rheumatol. 2014;33:49–55.CrossRefPubMedGoogle Scholar
  82. 82.
    Elkayam O, Jiries N, Dranitzki Z, Kivity S, Lidar M, Levy O, et al. Tocilizumab in adult-onset Still’s disease: the Israeli experience. J Rheumatol. 2014;41:244–7.CrossRefPubMedGoogle Scholar
  83. 83.
    Puéchal X, DeBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res. 2011;63:155–9.CrossRefGoogle Scholar
  84. 84.
    De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–95.CrossRefPubMedGoogle Scholar
  85. 85.
    Ma Y, Wu M, Zhang X, Xia Q, Yang J, Xu S, et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still’s disease: a meta-analysis. Mod Rheumatol. 2018;8:1–9.CrossRefGoogle Scholar
  86. 86.
    Watanabe E, Sugawara H, Yamashita T, Ishii A, Oda A, Terai C. Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset Still’s disease: a case-based review. Case Rep Med. 2016;2016:5656320.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Masui-Ito A, Okamoto R, Ikejiri K, Fujimoto M, Tanimura M, Nakamori S, et al. Tocilizumab for uncontrollable systemic inflammatory response syndrome complicating adult-onset Still disease: case report and review of literature. Medicine (Baltimore). 2017;96:e7596.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Tsuchida Y, Sumitomo S, Shoda H, Kubo K, Fujio K, Yamamoto K. Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still’s disease. Mod Rheumatol. 2017;27:556–7.CrossRefPubMedGoogle Scholar
  89. 89.
    Permal S, Wechsler B, Cabane J, Perrot S, Blum L, Imbert JC. Treatment of Still disease in adults with intravenous immunoglobulins. Rev Med Interne. 1995;16:250–4.CrossRefPubMedGoogle Scholar
  90. 90.
    Vignes S, Wechsler B, Amoura Z, Papo T, Francès C, Huong DL, et al. Intravenous immunoglobulin in adult Still’s disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 1998;16:295–8.PubMedGoogle Scholar
  91. 91.
    Prieur AM. Intravenous immunoglobulins in Still’s disease: still controversial, still unproven. J Rheumatol. 1996;23:797–800.PubMedGoogle Scholar
  92. 92.
    Ostrowski RA, Tehrani R, Kadanoff R. Refractory adult-onset still disease successfully treated with abatacept. J Clin Rheumatol. 2011;17:315–7.CrossRefPubMedGoogle Scholar
  93. 93.
    Quartuccio L, Maset M, De Vita S. Efficacy of abatacept in a refractory case of adult-onset Still’s disease. Clin Exp Rheumatol. 2010;28:265–7.PubMedGoogle Scholar
  94. 94.
    Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL. Successful treatment of refractory adult onset Still’s disease with rituximab. Ann Rheum Dis. 2006;65:1117–8.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Bartoloni E, Alunno A, Luccioli F, Santoboni G, Gerli R. Successful treatment of refractory adult-onset Still’s disease with anti-CD20 monoclonal antibody. Clin Exp Rheumatol. 2009;27:888–9.PubMedGoogle Scholar
  96. 96.
    Giampietro C, Ridene M, Lequerre T, Costedoat Chalumeau N, Amoura Z, Sellam J, et al. Anakinra in adult-onset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken). 2013;65:822–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Rheumatology Unit, Department of Medicine DIMEDUniversity of PadovaPaduaItaly

Personalised recommendations